Health Care & Life Sciences » Pharmaceuticals | BAFNA Pharmaceuticals Ltd.

BAFNA Pharmaceuticals Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
1,849
1,007
853
650
472
434
Cost of Goods Sold (COGS) incl. D&A
1,588
1,084
839
681
553
471
Gross Income
261
77
13
31
82
37
SG&A Expense
99
93
38
63
309
131
EBIT
161
192
36
98
391
168
Unusual Expense
-
1
30
2
-
-
Non Operating Income/Expense
6
414
7
10
313
17
Interest Expense
132
135
130
115
69
21
Pretax Income
25
61
153
204
147
173
Income Tax
10
2
2
9
22
11
Consolidated Net Income
14
62
151
195
169
184
Net Income
14
62
140
191
169
184
Net Income After Extraordinaries
14
62
140
191
169
184
Net Income Available to Common
14
62
140
191
169
184
EPS (Basic)
0.75
3.31
7.52
10.23
0.11
11.44
Basic Shares Outstanding
19
19
19
19
-
-
EPS (Diluted)
0.75
3.31
7.52
10.23
-
-
Diluted Shares Outstanding
19
19
19
19
-
-
EBITDA
251
132
12
56
351
133
Other Operating Expense
1
22
11
3
-
-
Non-Operating Interest Income
4
4
4
2
-
-
Minority Interest Expense
-
-
11
4
-
-

About BAFNA Pharmaceuticals

View Profile
Address
Bafna Towers
Chennai Tamil Nadu 600001
India
Employees -
Website http://www.bafnapharma.com
Updated 07/08/2019
Bafna Pharmaceuticals Ltd. is engaged in the manufacture of drugs and medicines of life saving drugs. Its brand portfolio includes Raricap, Raricap Forte, Raricap L Suspension and Raricap Combi. The company was founded in 1981 and is headquartered in Chennai, India.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.